This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (224)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Moirra K. Cruickshank, MD; Mark N. Levine, MD, MSc; Jack Hirsh, MD; Robin Roberts, MSc; Margaret Siguenza, RN

Arch Intern Med. 1991;151(2):333-337.

Abstract
A nomogram for the adjustment of heparin dosage was developed to standardize heparin therapy and to reduce delays in achieving and maintaining a therapeutic activated partial thromboplastin time (APTT) result. Fifty consecutive patients with acute venous thromboembolism had their continuous intravenous heparin therapy adjusted according to this heparin nomogram. The effect of the nomogram on heparin therapy in these patients was compared with data from 53 historical control patients. The proportion of patients in the nomogram group who reached a therapeutic APTT at 24 hours after the start of heparin therapy was 66%, which increased to 81% at 48 hours. In contrast, 37% and 58% of the control patients reached a therapeutic APTT at 24 and 48 hours, respectively. The percentage of therapeutic APTT results of the total number of APTT determinations was greater in the nomogram patients than controls. The use of this heparin nomogram resulted in (1) achieving a therapeutic APTT at 24 and 48 hours in a large proportion of patients and (2) reduced periods of inadequate anticoagulation and overanticoagulation during heparin therapy.

(Arch Intern Med. 1991;151:333-337)

Author Affiliations
From the Departments of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, and the Hamilton Civic Hospitals Research Centre. Dr Cruickshank is a research fellow of the Canadian Heart Foundation. Dr Levine is a scientist of the Medical Research Council of Canada.

Footnotes
Accepted for publication September 10, 1990.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Predictors of Initial Nontherapeutic Anticoagulation With Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction
Cheng et al.
Circulation 2009;119:1195-1202.
ABSTRACT | FULL TEXT  

Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Hirsh et al.
Chest 2008;133:141S-159S.
ABSTRACT | FULL TEXT  

The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Douketis et al.
Chest 2008;133:299S-339S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Kearon et al.
Chest 2008;133:454S-545S.
ABSTRACT | FULL TEXT  

Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Goodman et al.
Chest 2008;133:708S-775S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Monagle et al.
Chest 2008;133:887S-968S.
ABSTRACT | FULL TEXT  

Venous Thromboembolism and the Archives of Internal Medicine, 1908 to 2005
Dalen
Arch Intern Med 2008;168:14-15.
FULL TEXT  

How I treat venous thromboembolism in patients with cancer
Prandoni
Blood 2005;106:4027-4033.
ABSTRACT | FULL TEXT  

Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Hirsh and Raschke
Chest 2004;126:188S-203S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy for Venous Thromboembolic Disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Buller et al.
Chest 2004;126:401S-428S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy in Children*: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Monagle et al.
Chest 2004;126:645S-687S.
ABSTRACT | FULL TEXT  

Initial Treatment of Venous Thromboembolism
McRae and Ginsberg
Circulation 2004;110:I-3-I-9.
ABSTRACT | FULL TEXT  

Suboptimal Monitoring and Dosing of Unfractionated Heparin
Chung et al.
ANN INTERN MED 2004;140:582-582.
FULL TEXT  

Challenges to the Effective Use of Unfractionated Heparin in the Hospitalized Management of Acute Thrombosis
Hylek et al.
Arch Intern Med 2003;163:621-627.
ABSTRACT | FULL TEXT  

Validation of a Weight-Based Nomogram for the Use of Intravenous Heparin in Transient Ischemic Attack or Stroke
Toth and Voll
Stroke 2002;33:670-674.
ABSTRACT | FULL TEXT  

Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association
Hirsh et al.
Arterioscler. Thromb. Vasc. Bio. 2001;21 :e9-e9.
FULL TEXT  

Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association
Hirsh et al.
Circulation 2001;103:2994-3018.
FULL TEXT  

Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic Disease
Merli et al.
ANN INTERN MED 2001;134:191-202.
ABSTRACT | FULL TEXT  

Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
Hirsh et al.
Chest 2001;119 :64S-94S.
FULL TEXT  

Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers et al.
Chest 2001;119 :176S-193S.
FULL TEXT  

Antithrombotic Therapy in Children
Monagle et al.
Chest 2001;119 :344S-370S.
FULL TEXT  

Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy
Douketis et al.
Arch Intern Med 2000;160:3431-3436.
ABSTRACT | FULL TEXT  

Low molecular weight heparins for arterial thrombosis
Nenci and Minciotti
Vasc Med 2000;5:251-258.
ABSTRACT  

A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial
Ross et al.
J Am Coll Cardiol 1999;34:1954-1962.
ABSTRACT | FULL TEXT  

Anticoagulant Therapy of Pregnant Patients with Prosthetic Heart Valves : Rationale for a Clinical Trial of Low Molecular Weight Heparin
Messmore et al.
CLIN APPL THROMB HEMOST 1999;5:73-77.
ABSTRACT  

Thrombosis in the Emergency Department: Use of a Clinical Diagnosis Model to Safely Avoid the Need for Urgent Radiological Investigation
Anderson et al.
Arch Intern Med 1999;159:477-482.
ABSTRACT | FULL TEXT  

Prevention and treatment of venous thromboembolism after major trauma
Verstraete
Trauma 1999;1:39-51.
ABSTRACT  

Anticoagulation Therapy in Pediatric Patients With Sinovenous Thrombosis: A Cohort Study
deVeber et al.
Arch Neurol 1998;55:1533-1537.
ABSTRACT | FULL TEXT  

Abbreviated Hospitalization for Deep Venous Thrombosis With the Use of Ardeparin
Goldhaber et al.
Arch Intern Med 1998;158:2325-2328.
ABSTRACT | FULL TEXT  

Effect of Warfarin on Activated Partial Thromboplastin Time in Patients Receiving Heparin
Kearon et al.
Arch Intern Med 1998;158:1140-1143.
ABSTRACT | FULL TEXT  

Relation Between the Time to Achieve the Lower Limit of the APTT Therapeutic Range and Recurrent Venous Thromboembolism During Heparin Treatment for Deep Vein Thrombosis
Hull et al.
Arch Intern Med 1997;157:2562-2568.
ABSTRACT  

Effect of Weight, Sex, Age, Clinical Diagnosis, and Thromboplastin Reagent on Steady-state Intravenous Heparin Requirements
White et al.
Arch Intern Med 1997;157:2468-2472.
ABSTRACT  

Is There a Relationship Between the Intensity of Heparin Treatment and Recurrent Thomboembolism?
Anand et al.
CLIN APPL THROMB HEMOST 1997;3:S64-S67.
ABSTRACT  

Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
The Columbus Investigators
NEJM 1997;337:657-662.
ABSTRACT | FULL TEXT  

Induction of the Acute-Phase Reaction Increases Heparin-Binding Proteins in Plasma
Young et al.
Arterioscler. Thromb. Vasc. Bio. 1997;17:1568-1574.
ABSTRACT | FULL TEXT  

Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction
Collins et al.
NEJM 1997;336:847-860.
FULL TEXT  

Management of Venous Thromboembolism
Ginsberg
NEJM 1996;335:1816-1829.
FULL TEXT  

Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials
Collins et al.
BMJ 1996;313:652-659.
ABSTRACT | FULL TEXT  

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes
The Global Use of Strategies to Open Occluded Coro
NEJM 1996;335:775-782.
ABSTRACT | FULL TEXT  

The Effectiveness of Implementing the Weight-Based Heparin Nomogram as a Practice Guideline
Raschke et al.
Arch Intern Med 1996;156:1645-1649.
ABSTRACT  

The Relation Between the Activated Partial Thromboplastin Time Response and Recurrence in Patients With Venous Thrombosis Treated With Continuous Intravenous Heparin
Anand et al.
Arch Intern Med 1996;156:1677-1681.
ABSTRACT  

Venous Thromboembolism during Pregnancy
Toglia and Weg
NEJM 1996;335:108-114.
FULL TEXT  

Management of Deep Vein Thrombosis and Pulmonary Embolism : A Statement for Healthcare Professionals From the Council on Thrombosis (in Consultation With the Council on Cardiovascular Radiology), American Heart Association
Hirsh and Hoak
Circulation 1996;93:2212-2245.
FULL TEXT  

A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin Administered in the Hospital for Proximal Deep-Vein Thrombosis
Levine et al.
NEJM 1996;334:677-681.
ABSTRACT | FULL TEXT  

Activated Partial Thromboplastin Time and Outcome After Thrombolytic Therapy for Acute Myocardial Infarction : Results From the GUSTO-I Trial
Granger et al.
Circulation 1996;93:870-878.
ABSTRACT | FULL TEXT  

A Critical Pathway to Evaluate Suspected Deep Vein Thrombosis
Pearson et al.
Arch Intern Med 1995;155:1773-1778.
ABSTRACT  

Quality Assurance of High-Dose IV Heparin Treatment Exemplified by Patients Implanted with Coronary Palmaz-Schatz Stents
Haushofer et al.
ANGIOLOGY 1995;46:305-311.
ABSTRACT  

Appropriate Use of Heparin: Empiric vs Nomogram-Based Dosing
Gunnarsson et al.
Arch Intern Med 1995;155:526-532.
ABSTRACT  

A Review of Common Approaches to Heparin Dosing
Hodgman
Journal of Pharmacy Practice 1995;8:39-46.
ABSTRACT  

Some Familiar Trade-offs
Pauker and Kopelman
NEJM 1994;331:1511-1515.
FULL TEXT  

Use of a Standardized Heparin Nomogram to Achieve Therapeutic Anticoagulation After Thrombolytic Therapy in Myocardial Infarction
Flaker et al.
Arch Intern Med 1994;154:1492-1496.
ABSTRACT  

Physician-Guided Treatment Compared With a Heparin Protocol for Deep Vein Thrombosis
Elliott et al.
Arch Intern Med 1994;154:999-1004.
ABSTRACT  

Computer-Assisted Dosing of Heparin: Management With a Pharmacy-Based Anticoagulation Service
Kershaw et al.
Arch Intern Med 1994;154:1005-1011.
ABSTRACT  

A Randomized Trial Comparing Activated Thromboplastin Time With Heparin Assay in Patients With Acute Venous Thromboembolism Requiring Large Daily Doses of Heparin
Levine et al.
Arch Intern Med 1994;154:49-56.
ABSTRACT  

Recent Developments in the Diagnosis, Treatment, and Prevention of Pulmonary Embolism
Hastings et al.
Arch Fam Med 1993;2:655-669.
ABSTRACT  

Standardization of Heparin Therapy Improves Efficacy-Reply
Levine
Arch Intern Med 1992;152:2413-2413.
ABSTRACT  

Standardization of Heparin Therapy Improves Efficacy
Bras and Halfon
Arch Intern Med 1992;152:2140-2413.
ABSTRACT  

Optimal Therapeutic Level of Heparin Therapy in Patients With Venous Thrombosis
Hull et al.
Arch Intern Med 1992;152:1589-1595.
ABSTRACT  

Clinical Use of the Heparin Nomogram
Raschke and Hertel
Arch Intern Med 1991;151:2318-2321.
ABSTRACT